Results 201 to 210 of about 16,883 (239)

Dolutegravir

Reactions Weekly, 2017
  +11 more sources

Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir Study

Journal of Acquired Immune Deficiency Syndromes
Supplemental Digital Content is Available in the Text. Background: Dolutegravir dispersible tablets (DTG-DTs) are approved for infants 4 weeks or older and ≥3 kg but their suitability for neonates remains unknown.
T. Cressey, Nicolas Salvadori, H. Rabie, Samantha du Toit, K. Than-in-at, Maria Groenewald, Edmund Capparelli, A. Owen, R. Cressey, Marc Lallemant, Mark F. Cotton, Adrie Bekker   +11 more
semanticscholar   +1 more source

Second-Line Switch to Dolutegravir for Treatment of HIV Infection.

New England Journal of Medicine, 2023
BACKGROUND Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype information and who have viral suppression with second ...
L. Ombajo, Jeremy Penner, Joseph Nkuranga, Jared Mecha, M. Mburu, C. Odhiambo, Florentius Ndinya, Rukia Aksam, Richard Njenga, Simon K Wahome, P. Muiruri, S. Eshiwani, Maureen Kimani, Catherine Ngugi, A. Pozniak   +14 more
semanticscholar   +1 more source

Dolutegravir

Reactions Weekly, 2019
  +11 more sources

Real world use of dolutegravir two drug regimens

AIDS (London), 2023
Background: Since 2015, we prescribed dolutegravir (DTG)-based two drug regimens (DTG-2DR) for 620 people [total cohort 3133 (19.8%)]. Method: Clinic database search 1 January 15 to 31 October 21.
Conor Bowman, Alissa Ambrose, Tanmay Kanitkar, Katia Flores, P. Simões, J. Hart, A. Hunter, Jane Akodu, T. Barber   +8 more
semanticscholar   +1 more source

Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers

Clinical pharmacology and therapy
This study was designed to assess the quantitative performance of endogenous drug–drug interaction (DDI) biomarkers (N1‐methylnicotinamide (1‐NMN), N1‐methyladenosine (m1A), and creatinine) for the organic cation transporters, OCT2 and MATE1/2K in the ...
Tomoki Koishikawa, Kaku Fujiwara, Kunal S. Taskar, Maciej J. Zamek-Gliszczynski, Kenta Yoshida, Xiaoyan Chu, Hideki Hirabayashi, Jialin Mao, K. Rockich, Tadayuki Takashima, Y. Yamaura, Yurong Lai, Yukana Tomoda, Tomoko Kito, K. Maeda, Kenichi Furihata, Yuichi Sugiyama, H. Kusuhara   +17 more
semanticscholar   +1 more source

Dolutegravir

Reactions Weekly, 2023
  +7 more sources

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings.

Journal of Antimicrobial Chemotherapy, 2023
BACKGROUND This work aims to evaluate integrase resistance and its predictors in HIV-1 infected combined antiretroviral therapy (cART) experienced individuals failing a dolutegravir-based regimen.
D. Armenia, M. Santoro, C. Charpentier, A. Bertoli, F. Forbici, V. Calvez, D. Descamps, F. Ceccherini‐Silberstein, A. Marcelin, P. Flandre   +9 more
semanticscholar   +1 more source

Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial.

Clinical Infectious Diseases, 2023
BACKGROUND Integrase inhibitors have been recently linked to a higher risk for hypertension. In NEAT022 randomized trial, virologically suppressed persons with HIV (PWH) with high cardiovascular risk switched from protease inhibitors to dolutegravir ...
Abiu Sempere, L. Assoumou, A. González-Cordón, L. Waters, S. Rusconi, P. Domingo, M. Gompels, S. De Wit, F. Raffi, C. Stephan, M. Masiá, J. Rockstroh, C. Katlama, G. Behrens, G. Moyle, Margaret A. Johnson, J. Fox, H. Stellbrink, G. Guaraldi, E. Florence, S. Esser, J. Gatell, A. Pozniak, E. Martinez   +23 more
semanticscholar   +1 more source

Virologic Failure and Drug Resistance After Programmatic Switching to Dolutegravir-based First-line Antiretroviral Therapy in Malawi and Zambia

Clinical Infectious Diseases
Background People with human immunodeficiency virus (PWH) on first-line, nonnucleoside reverse-transcriptase inhibitor–based antiretroviral therapy (ART) were routinely switched to tenofovir-lamivudine-dolutegravir.
V. Skrivankova, J. Huwa, G. Muula, G. Chiwaya, Esau Banda, Shameem Buleya, B. Chihota, J. Chintedza, Carolyn Bolton, H. Tweya, T. Kalua, Stefanie Hossmann, R. Kouyos, G. Wandeler, M. Egger, R. Lessells   +15 more
semanticscholar   +1 more source